IPM 014A

Phase:II, I
Principal Investigator(s):Dr Annalene Nel
Objective:The purpose of this study is to determine whether dapivirine gel 4759 is safe for daily use by healthy women in Kenya, Malawi, Rwanda, South Africa and Tanzania.
Prevention Option(s):Microbicides
Study Design:Randomized
Arms and Assigned Interventions
Descriptiondosage: 1.25mg dapivirine/day frequency: once daily duration: 6 weeks
Mode of DeliveryGel
Official Code: NCT00917891
Trial Sponsors: IPM
Start Date
End Date
September 1, 2009
September 1, 2011
Age range: 18 Years ↔ 40 Years
Population:Cisgender Women